

# CITATION REPORT

List of articles citing

Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease

DOI: 10.1016/0140-6736(90)93028-n  
Lancet, The, 1990, 335, 1484-7.

**Source:** <https://exaly.com/paper-pdf/21797807/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
116	Brain single photon emission computed tomography: newer activation and intervention studies. <b>1991</b> , 21, 40-57		20
115	Intravenous L-tryptophan and regional cerebral blood flow. <b>1991</b> , 29, 508-9		9
114	Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. <i>British Journal of Psychiatry</i> , <b>1991</b> , 158, 558-62	5.4	11
113	Clinical Diagnosis of Alzheimer's Disease. <b>1991</b> , 2, 186-194		
112	Single photon emission tomography in Alzheimer's disease. A longitudinal study of changes in relative regional cerebral blood flow. <b>1991</b> , 6, 767-774		5
111	A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. <b>1992</b> , 55, 1182-7		123
110	Alzheimer's disease in adults with Down's syndrome: the relationship between regional cerebral blood flow equivalents and dementia. <b>1992</b> , 86, 340-5		24
109	'Traditional' pharmacotherapy may succeed in Alzheimer's disease. <b>1992</b> , 15, 84-5		22
108	Dialysis or diffusion?. <b>1992</b> , 15, 85		4
107	Animal and drug modelling for Alzheimer synaptic pathology. <b>1992</b> , 39, 517-45		39
106	Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. <b>1992</b> , 13, 747-58		135
105	Effect of the 5-HT <sub>1A</sub> partial agonist buspirone on regional cerebral blood flow in man. <b>1992</b> , 108, 380-6		24
104	Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. <b>1992</b> , 108, 103-9		52
103	The effects of tacrine on regional cerebral blood flow in Alzheimer's disease. <b>1992</b> , 7, 835-838		3
102	Clinical studies in Alzheimer patients with positron emission tomography. <b>1993</b> , 57, 215-24		59
101	Cerebral blood flow in patients with dementia of Alzheimer's type. <b>1993</b> , 5, 19-26		10
100	Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer disease. <b>1993</b> , 70, 39-56		28

99	Cholinergic treatment of an amnesic man with a basal forebrain lesion: theoretical implications. <b>1993</b> , 56, 1282-9	48
98	A single photon emission computerised tomography study of regional brain function underlying verbal memory in patients with Alzheimer-type dementia. <i>British Journal of Psychiatry</i> , <b>1993</b> , 163, 166-72 <sup>5.4</sup>	31
97	A study of regional cerebral blood flow using 99mTc-HMPAO-SPECT in elderly women with senile dementia of Alzheimer's type. <b>1994</b> , 5, 302-9	6
96	Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,l-HMPAO SPECT study. <b>1994</b> , 57, 285-95	72
95	Functional neuroimaging in Alzheimer's disease: how far should we go?. <b>1994</b> , 21, 1041-3	1
94	The value of single photon emission tomography in psychopharmacology. <b>1994</b> , 9, 357-364	1
93	Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. <b>1994</b> , 123, 44-51	23
92	Nicotinic cholinergic receptors associated with mammalian cerebral vessels. <b>1994</b> , 49 Suppl, S3-7	36
91	The Role of Cholinesterase Inhibitors in Alzheimer's Disease. <b>1994</b> , 1, 146-165	26
90	SPECT in dementia: clinical and pathological correlation. <b>1995</b> , 43, 1243-7	74
89	Differentiation between Alzheimer's disease and multi-infarct dementia: Spect vs MR imaging. <b>1995</b> , 10, 121-128	11
88	Current pharmacological strategies in Alzheimer's disease. <b>1995</b> , 10, 633-646	1
87	Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. <b>1995</b> , 121, 231-41	27
86	Regional cerebral blood flow measured by 99mTc-HMPAO SPECT differs in subgroups of Alzheimer's disease. <b>1995</b> , 9, 95-109	14
85	A neurochemical approach for studying response to acetylcholine in Alzheimer's disease. <b>1995</b> , 20, 769-71	14
84	Neuropsychological tests and [99mTc]-HM PAO SPECT in the diagnosis of Alzheimer's dementia. <b>1995</b> , 242, 359-66	17
83	Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicysteinate retention in Alzheimer's disease measured with single photon emission computed tomography imaging. <b>1995</b> , 195, 53-6	6
82	Skin vessel reactivity is impaired in Alzheimer's disease. <b>1995</b> , 16, 577-82	18

81	Muscarinic M1-Receptor Agonists. <b>1995</b> , 3, 467-481	12
80	Cholinergic control of cerebral blood flow in stroke, trauma and aging. <b>1996</b> , 58, 2011-8	33
79	Effect of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism. <b>1996</b> , 17, 849-57	9
78	Functional studies of new drugs for the treatment of Alzheimer's disease. <b>1996</b> , 165, 137-44	11
77	Chronic nicotine treatment prevents neuronal loss in neocortex resulting from nucleus basalis lesions in young adult and aged rats. <b>1996</b> , 27, 285-305	12
76	Cerebral vessels in ageing and Alzheimer's disease. <b>1996</b> , 72, 193-214	258
75	SPECT measurements of brain function in dementia; a review. <b>1996</b> , 168, 54-8	17
74	SPET scanning in Alzheimer's Disease and the effects of tacrine on regional cerebral blood flow. <b>1996</b> , 11, 343-348	
73	Assessment of brain SPECT. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <b>1996</b> , 46, 278-85	82
72	A double-blind, placebo-controlled study of tacrine in patients with Alzheimer's disease using SPET. <b>1996</b> , 10, 175-81	3
71	Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. <b>1997</b> , 9 Suppl 1, 11-38	23
70	Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients. <b>1997</b> , 6, 335-43	36
69	Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. <b>1997</b> , 94, 6512-6	201
68	Clinical studies of cerebral blood flow in Alzheimer's disease. <b>1997</b> , 826, 254-62	73
67	Physostigmine reversal of scopolamine-induced hypofrontality. <b>1997</b> , 17, 220-8	39
66	The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. <b>1997</b> , 132, 217-26	17
65	The Pharmacology of Physostigmine. <b>1998</b> , 4, 87-136	108
64	Effects of damage to the basal forebrain on brain glucose utilization: a reevaluation using positron emission tomography in baboons with extensive unilateral excitotoxic lesion. <b>1998</b> , 18, 476-90	17

63	Use of automated image registration to generate mean brain SPECT image of Alzheimer's patients. <b>1998</b> , 12, 127-32	5
62	Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. <b>1998</b> , 13, 211-22	7
61	Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. <i>Brain</i> , <b>1999</b> , 122 ( Pt 8), 1519-31	11.2 169
60	Tc-99m HMPAO SPECT in the evaluation of Alzheimer's disease: correlation between neuropsychiatric evaluation and CBF images. <b>1999</b> , 66, 228-32	24
59	SPECT patterns in probable Alzheimer's disease. <b>1999</b> , 249, 190-6	13
58	Selective immunotoxin-induced cholinergic deafferentation alters blood flow distribution in the cerebral cortex. <b>1999</b> , 818, 1-11	25
57	The cholinergic hypothesis of Alzheimer's disease: a review of progress. <b>1999</b> , 66, 137-47	1373
56	Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. <b>1999</b> , 92, 163-75	129
55	Time course of pharmacodynamic and pharmacokinetic effects of physostigmine assessed by functional brain imaging in humans. <b>2000</b> , 66, 475-81	28
54	Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinergic enzyme-positive structures in the human and rat brain. <b>2000</b> , 101, 89-100	69
53	Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. <b>2000</b> , 51, 213-8	95
52	Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. <b>2001</b> , 49, 211-20	61
51	Neuroimaging in Alzheimer's disease: relevance for treatment. <b>2001</b> , 3, 13-9	6
50	EEG Correlates of Mild Impairments of Higher Cortical Functions. <b>2001</b> , 27, 1-8	2
49	Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. <b>2001</b> , 98, 14096-101	219
48	Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions?. <b>2002</b> , 13, 95-165	37
47	Single-photon Emission Computerized Tomography (SPECT). 363-368	
46	Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. <b>2002</b> , 13, 83-7	93

45	A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. <b>2002</b> , 109, 857-70	70
44	The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. <b>2003</b> , 216, 119-26	60
43	Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. <b>2003</b> , 74, 345-53	52
42	Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. <b>2003</b> , 24, 414-20	95
41	M 1 -M 5 Muscarinic Receptor Knockout Mice as Novel Tools to Study the Physiological Roles of the Muscarinic Cholinergic System. <b>2003</b> , 9, 279-290	46
40	Degeneration of the basalocortical pathway from the cortex induces a functional increase in galaninergic markers in the nucleus basalis magnocellularis of the rat. <b>2004</b> , 24, 1255-66	9
39	Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. <b>2004</b> , 44, 423-50	320
38	Neurochemical imaging of dementias. <b>2004</b> , 34, 70-82	16
37	Regional cortical blood flow changes following sodium lactate infusion in Alzheimer's disease. <b>2005</b> , 21, 1671-8	7
36	Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography. <b>2005</b> , 59, 280-90	21
35	Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. <b>2006</b> , 61, 267-71	59
34	Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice. <b>2006</b> , 24, 334-44	62
33	Symptomatic treatment of Alzheimer's disease: identification of biomarkers to aid translation from bench to bedside. <b>2007</b> , 1, 93-110	
32	Imaging treatment effects in Alzheimer's disease. <b>2007</b> , 25, 953-68	32
31	The hemo-neural hypothesis: on the role of blood flow in information processing. <b>2008</b> , 99, 2035-47	151
30	Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War. <b>2009</b> , 171, 207-20	34
29	Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease. <b>1993</b> , 149, 39-41	6
28	Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. <b>1993</b> , 149, 62-5	17

27	The short-term effect of acetylcholinesterase inhibitor on the regional cerebral blood flow of Alzheimer's disease. <b>2010</b> , 50, 222-6		2
26	Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors. <b>2010</b> , 45, 5602-11		19
25	Parasympathetic control of blood flow to the activated human brain. <b>2010</b> , 95, 980-1		2
24	Altered neural cholinergic receptor systems in cocaine-addicted subjects. <b>2010</b> , 35, 1485-99		35
23	Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging. <b>2011</b> , 94, 360-88		117
22	Review: cerebral microvascular pathology in ageing and neurodegeneration. <b>2011</b> , 37, 56-74		468
21	Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction?. <b>2011</b> , 5, 25-35		26
20	The effects of blood pressure and the renin-angiotensin-aldosterone system on regional cerebral blood flow and cognitive impairment in dialysis patients. <b>2014</b> , 37, 636-41		8
19	Cognitive impairment and cardiovascular disease: so near, so far. <b>2014</b> , 175, 21-9		44
18	Cerebral Vascular Control and Metabolism in Heat Stress. <b>2015</b> , 5, 1345-80		55
17	Enhanced Cholinergic Activity Improves Cerebral Blood Flow during Orthostatic Stress. <b>2017</b> , 8, 103		9
16	Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid- $\beta$ -42 and Hypertension. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 66, 1095-1104	4.3	16
15	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, 1917-1933	11.2	492
14	The Muscarinic Acetylcholine Receptor M: Therapeutic Implications and Allosteric Modulation. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 1025-1034	5.7	12
13	Single Photon Emission Tomography. <b>1994</b> , 437-456		1
12	Muscarinic Acetylcholine Receptor Knockout Mice. <i>Handbook of Experimental Pharmacology</i> , <b>2004</b> , 65-93	3.2	3
11	Follow-up of improvement in regional cerebral blood flow and mental status in Alzheimer's disease: a case report. <i>Clinical Nuclear Medicine</i> , <b>1998</b> , 23, 601-3	1.7	2
10	Low blood pressure in Down's syndrome, A link with Alzheimer's disease?. <i>Hypertension</i> , <b>1996</b> , 28, 569-75	3.5	44

- 9 Editorial Preface. *British Journal of Psychiatry*, **1990**, 157, 7-9 5-4 5
- 8 The Use and Applications of Single-Photon Emission Computerised Tomography in Dementia. *British Journal of Psychiatry*, **1990**, 157, 66-75 5-4 19
- 7 Dementia and Cerebrovascular Disease. **2004**, 176-199
- 6 Physiological Neuroimaging in Ageing and Dementia: Metabolic and Molecular Scanning. **2010**, 257-261
- 5 Use of SPECT in Early Diagnosis and to Monitor the Effect of Drugs in Alzheimer Disease. **1994**, 417-423 1
- 4 Neuronal pathology in relation to molecular biology and treatment of Alzheimer's disease. *Molecular and Cell Biology of Human Diseases Series*, **1994**, 4, 25-54
- 3 SPECT in dementia, schizophrenia and other psychiatric disorders. **1997**, 131-160
- 2 Spect Scan and Efficacy of Therapy in Alzheimer's Disease. **1997**, 457-461
- 1 The Rationale for Development of Cholinergic Therapies in ad. *Advances in Behavioral Biology*, **1998**, 445-450